{
  "id": 1767428763669,
  "title": "MYASTHENIA GRAVIS & NMJ DISORDERS",
  "summary": "An exhaustive guide to Myasthenia Gravis (MG), the 'Great Mimic' of neuromuscular diseases, covering its autoimmune pathogenesis, bimodal distribution, fatiguable clinical signs, and management protocols alongside related syndromes like LEMS and various toxins.",
  "date": "2026-01-03T08:26:03.669Z",
  "data": {
    "title": "MYASTHENIA GRAVIS & NMJ DISORDERS",
    "summary": "An exhaustive guide to Myasthenia Gravis (MG), the 'Great Mimic' of neuromuscular diseases, covering its autoimmune pathogenesis, bimodal distribution, fatiguable clinical signs, and management protocols alongside related syndromes like LEMS and various toxins.",
    "summary_illustration": "<svg viewBox='0 0 200 100' xmlns='http://www.w3.org/2000/svg'><path d='M20 50 Q100 0 180 50 Q100 100 20 50' stroke='hsl(215, 90%, 45%)' fill='none' stroke-width='2'/><path d='M40 45 Q100 15 160 45' stroke='hsl(215, 90%, 45%)' fill='none' stroke-width='4' stroke-linecap='round'><animate attributeName='d' values='M40 45 Q100 15 160 45;M40 55 Q100 65 160 55;M40 45 Q100 15 160 45' dur='3s' repeatCount='indefinite'/></path><circle cx='100' cy='50' r='12' fill='hsl(215, 90%, 45%)'/></svg>",
    "sections": [
      {
        "title": "Disease Overview & Epidemiology",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "MG is an uncommon autoimmune disease characterized by weakness and fatiguability of skeletal muscle.",
          "Pathogenesis: Antibodies against post-synaptic acetylcholine (ACh) receptors are the most commonly identified autoantibodies.",
          "Prevalence: Estimated as up to 1 in 10,000.",
          "Distribution: Bimodal distribution with peaks at about 20y and 60y.",
          "Younger group (20y): Commoner in females (♀).",
          "Older group (60y): Commoner in males (♂).",
          "Associations: Thymic hyperplasia and other autoimmune diseases (e.g., Graves’ disease in 4–10%)."
        ]
      },
      {
        "title": "The 'Great Mimic': Clinical Features",
        "icon": "theater_comedy",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "center": "Clinical MG",
          "branches": [
            "Ocular Motility: Consider MG for abnormalities that 'do not fit' or are highly variable.",
            "Presentation: Ocular signs in 70% at onset; 90% at some point.",
            "Generalization: Ocular MG becomes generalized in 80% (usually within 2y)."
          ]
        }
      },
      {
        "title": "Ocular Signs & Fatigue Testing",
        "icon": "visibility",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "Variable diplopia or ptosis (usually worsening towards evening/with exercise).",
          "Variable and fatiguable ptosis or ocular motility disturbance (any pattern).",
          "Sustained eccentric gaze (≥1min) or repeated saccades demonstrate fatigue (e.g., prolonged upward gaze fatigues LPS and elevators).",
          "Cogan’s twitch: Ask patient to look down for 20s then at object in 1° position; positive if the lid 'overshoots'.",
          "Spontaneous twitching: A sign of severe fatigue."
        ]
      },
      {
        "title": "Systemic Features & Fatal Risks",
        "icon": "warning",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "FATIGUABLE WEAKNESS: Limbs, speech, chewing, swallowing, breathing.",
          "CHOKING & BULBAR: Fluids going up the nose when swallowing.",
          "CRITICAL WARNING: MG is potentially fatal due to respiratory failure or choking.",
          "ACTION: Take breathlessness or any choking episodes seriously."
        ]
      },
      {
        "title": "Antibody Investigations",
        "icon": "science",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Antibody Type",
            "Prevalence/Context"
          ],
          "rows": [
            [
              "Anti-ACh Receptor",
              ">90% in generalized MG; 50% in ocular MG."
            ],
            [
              "MuSK (Muscle-specific tyrosine kinase)",
              "Present in 5%."
            ],
            [
              "LRP4 (Low-density lipoprotein-related receptor protein 4)",
              "Found in some double seronegative; thought to be pathogenic."
            ],
            [
              "Non-pathogenic Markers",
              "Agrin, Ryanonide, Titin, and Cortactin (found in seropositive and seronegative)."
            ],
            [
              "Anti-skeletal muscle",
              "85% of patients with thymoma."
            ],
            [
              "Other Labs",
              "Test thyroid function/antibodies in all; ANA for associated disease."
            ]
          ]
        }
      },
      {
        "title": "Clinical & Imaging Tests",
        "icon": "clinical_notes",
        "type": "process",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "1. EMG: Repetitive nerve stimulation (initial); if negative, consider single EMG on symptomatic muscles. (Ref 35)",
          "2. Thymus Scanning: CT or MRI imaging required for all suspected patients. (Ref 35)",
          "3. Ice-pack Test: Apply for 2min to closed eyelid; positive if ptosis improves by ≥2mm.",
          "4. Pharmacological Test: Neostigmine or pyridostigmine via MG expert. (NB: Tensilon®/edrophonium discontinued)."
        ]
      },
      {
        "title": "Treatment & Management",
        "icon": "medication",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Specialist Liaison: Liaise with MG specialist to optimize care and assess systemic involvement.",
          "Anticholinesterases: Pyridostigmine 30–60mg PO 1–2×/d; increase to max 450mg/d. Use propantheline for GI disturbance.",
          "Immunosuppression: For generalized disease—corticosteroids, azathioprine, IV immunoglobulin, plasmapheresis. (Ref 35)",
          "Thymectomy (Non-thymomatous): Benefits clinical outcomes and reduces drug requirements (prednisone/azathioprine) for up to 3y. (Ref 36)",
          "Thymectomy (Thymomatous): Absolute indication for surgery."
        ]
      },
      {
        "title": "Prognosis & Emergency Care",
        "icon": "monitoring",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Fatal cardiorespiratory failure rarely occurs, usually in the first year.",
          "At-risk patients: Nurse sitting upright; may require nasogastric tube due to choking risk.",
          "Worse Prognosis: Associated with thymoma and late disease onset.",
          "Positive Outlook: Most patients well controlled; some spontaneously remit."
        ]
      },
      {
        "title": "Lambert-Eaton (LEMS) & Congenital",
        "icon": "account_tree",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Congenital Myasthenia: Heterogeneous group; presynaptic, synaptic, or post-synaptic AChR defects. Occurs throughout childhood; often purely ocular.",
          "LEMS Pathogenesis: Disorder of presynaptic calcium channels; impaired ACh release.",
          "LEMS Association: Usually malignancy (e.g., small cell lung cancer) or isolated autoimmune.",
          "LEMS Ocular: Decreased lacrimation, motility abnormalities, tonic pupils.",
          "LEMS Key Difference: Repeated/sustained testing causes improvement (unlike MG)."
        ]
      },
      {
        "title": "Toxins & Nerve Agents",
        "icon": "skull",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "red",
        "content": {
          "center": "Toxins",
          "branches": [
            "Impair ACh Release: Botulism, Tick paralysis.",
            "Increase ACh Release: Black widow spider, Scorpion bite.",
            "Acetylcholinesterase Inhibition: Organophosphates (fertilizers, nerve gas).",
            "Treatment: Supportive, Antitoxin, Atropine blockade (excitatory)."
          ]
        }
      },
      {
        "title": "Table 16.26: NMJ Disorders Comparison",
        "icon": "list_alt",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Syndrome",
            "Pathogenesis",
            "Ocular Features",
            "Systemic Features"
          ],
          "rows": [
            [
              "MG (Inhibitory)",
              "Antibodies to postsynaptic AChR",
              "Fatiguable ptosis, abnormal motility",
              "Fatigue of limbs, bulbar function, respiratory failure"
            ],
            [
              "LEMS (Inhibitory)",
              "Paraneoplastic presynaptic ↓ACh release",
              "↓lacrimation, tonic pupils, abnormal motility",
              "Proximal weakness, Autonomic dysfunction"
            ],
            [
              "Botulism (Inhibitory)",
              "Toxin presynaptic ↓ACh release",
              "Ptosis, tonic pupils, abnormal motility",
              "Weakness of bulbar function, Autonomic dysfunction"
            ],
            [
              "Organophosphate (Excitatory)",
              "Toxin inhibits acetylcholinesterase",
              "Miosis",
              "Respiratory failure, Fasciculation, Paralysis"
            ],
            [
              "Scorpion toxin (Excitatory)",
              "Toxin Presynaptic ↑ACh release",
              "↓VA, abnormal motility",
              "Respiratory failure, Mental disturbance"
            ]
          ]
        }
      },
      {
        "title": "References",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "35 Sussman J et al. Myasthenia gravis: Association of British Neurologists’ management guidelines. Pract Neurol. 2015;15:199–206. 36 Wolfe G et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–22."
      }
    ]
  },
  "chapterId": "neuro",
  "seqId": 8,
  "_serverSynced": true
}